

IN THE UNITED STATES DESIGNATED OFFICE (DO/US)

In re: Wong *et al.*

Attn: PCT Legal Staff

International Appl. No.: PCT/US2003/026612

International Filing Date: 25 August 2003

U.S. Application No. 10/525,535

For: COMPOSITIONS AND METHODS OF THERAPY FOR CANCERS  
CHARACTERIZED BY EXPRESSION OF THE TUMOR-ASSOCIATED  
ANTIGEN MN/CA IX

Mail Stop PCT

Attention: PCT Legal Staff

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450


**STATEMENT IN SUPPORT OF FILING A SEQUENCE LISTING  
UNDER 37 CFR § 1.821(c) and (e)**

Sir:

In response to the Notification of Missing Requirements (Form PCT/DO/EO/905) for the above-referenced application, Applicants submit herewith an initial computer readable form (CRF) of the Sequence Listing that was filed for International Application No. PCT/US2003/026612 on 25 August 2003. The CRF of the Sequence Listing has been amended to insert the current application number (US 10/525,535) and its filing date (23 February 2005) in fields <140> and <141>, respectively, and to insert the application number for corresponding International Patent Application No. PCT/US2003/026612 and its filing date (25 August 2003) in fields <150> and <151>.

I hereby state that, with the exception of the application data inserted as noted herein above, the content of the paper copy of the Sequence Listing that was filed for International Application No. PCT/US2003/026612 on 25 August 2003, and the content of the CRF of this Sequence Listing submitted concurrently herewith in accordance with 37 CFR § 1.821(c) and (e), are the same.

Respectfully submitted,



Leslie T. Henry  
Agent for Applicants  
Registration No. 45,714

**Customer No. 27476**  
NOVARTIS VACCINES AND  
DIAGNOSTICS, INC.  
Corporate Intellectual Property R338  
P.O. Box 8097  
Emeryville, CA 94662-8097 US

**ELECTRONICALLY FILED USING THE EFS-WEB  
ELECTRONIC FILING SYSTEM OF THE UNITED STATES  
PATENT & TRADEMARK OFFICE ON March 6, 2007.**